Findings

What do systematic reviews say?

147 questions · 147 findings · 66 reviews · Heart

Sort:Best matchNewest Highest certainty Download CSV

No studies found 25 · 17%GRADE not reported 2 · 1.4%Very low 42 · 28.6%Low 35 · 23.8%Moderate 28 · 19%High 15 · 10.2%

Exercise‐based cardiac rehabilitation vs usual care

All‐cause mortality · adults with heart failure

Exercise‐based cardiac rehabilitation showed no clear difference in all‐cause mortality compared with usual care (low certainty).

1 finding from 1 review

Exercise‐based cardiac rehabilitation for adults with heart failure 2024 · Cochrane Headline outcomes only
RR 0.93 [0.71, 1.21]
34 studies · 3941 participants
Low

Class I antiarrhythmics vs control

All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class III antiarrhythmics vs control

All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation

It is very uncertain whether class III antiarrhythmics changes all‐cause mortality compared with control (very low certainty).

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
Peto OR 0.13 [0, 6.57]
1 study · 212 participants
Very low

Class I and/or III antiarrhythmics vs control

All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation

Class I and/or III antiarrhythmics showed no clear difference in all‐cause mortality compared with control (low certainty).

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
Peto OR 1 [0.06, 16.24]
1 study · 90 participants
Low

Intervention not reported

All‐cause mortality

The intervention showed no clear difference in all‐cause mortality (low certainty).

1 finding from 1 review

Social network interventions to support cardiac rehabilitation and secondary prevention in the management of people… 2023 · Cochrane Headline outcomes only
RR 0.75 [0.49, 1.13]
6 studies · 3093 participants
Low

Effects of high‐ vs low‐added sugar consumption

All‐cause mortality · Adults without diabetes or CVD

The review found no eligible studies for this question.

1 finding from 1 review

High versus low‐added sugar consumption for the primary prevention of cardiovascular disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High vs low blood pressure target

All‐cause mortality · adults undergoing cardiac surgery with cardiopulmonary bypass

It is very uncertain whether high changes all‐cause mortality compared with low blood pressure target (very low certainty).

1 finding from 1 review

High versus low blood pressure targets for cardiac surgery while on cardiopulmonary bypass 2022 · Cochrane Headline outcomes only
RR 1.33 [0.3, 5.9]
3 studies · 737 participants
Very low

Intervention not reported

All‐cause mortality · healthy normal weighted participants recruited through leaflets from Italy

The review found no eligible studies for this question.

1 finding from 1 review

Effects of a gluten‐reduced or gluten‐free diet for the primary prevention of cardiovascular disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ultrafiltration (UF) vs usual care

All‐cause mortality · people with AHF

It is very uncertain whether ultrafiltration (UF) changes all‐cause mortality compared with usual care (UC) (very low certainty).

1 finding from 1 review

Ultrafiltration for acute heart failure 2022 · Cochrane Headline outcomes only
RR 0.61 [0.13, 2.85]
3 studies · 286 participants
Very low

Exercise‐based cardiac rehabilitation vs no exercise

All‐cause mortality · patients with coronary heart disease

Exercise‐based cardiac rehabilitation showed no clear difference in all‐cause mortality compared with 'no exercise' control (moderate certainty).

1 finding from 1 review

Exercise‐based cardiac rehabilitation for coronary heart disease 2021 · Cochrane Headline outcomes only
RR 0.87 [0.73, 1.04]
25 studies · 8823 participants
Moderate

Coenzyme Q10 vs placebo or conventional therapy

All‐cause mortality · patients with heart failure

Coenzyme Q10 probably leads to lower all‐cause mortality compared with placebo or conventional therapy (moderate certainty).

1 finding from 1 review

Coenzyme Q10 for heart failure 2021 · Cochrane Headline outcomes only
RR 0.58 [0.35, 0.95]
1 study · 420 participants
Moderate

Exercise vs no exercise

All‐cause mortality · adults after heart valve surgery

It is very uncertain whether exercise changes all‐cause mortality compared with no exercise (very low certainty).

1 finding from 1 review

Exercise‐based cardiac rehabilitation for adults after heart valve surgery 2021 · Cochrane Headline outcomes only
RR 0.83 [0.26, 2.68]
2 studies · 131 participants
Very low

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

All‐cause mortality · patients with chronic heart failure with preserved ejection fraction

Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in all‐cause mortality compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.91 [0.78, 1.06]
5 studies · 4207 participants
Moderate

Stem cell therapy vs control

All‐cause mortality · DCM (non‐ischaemic)

It is very uncertain whether stem cell therapy changes all‐cause mortality compared with control (very low certainty).

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
RR 0.84 [0.54, 1.31]
7 studies · 361 participants
Very low

Stem cell therapy vs peripheral therapy with granulocyte colony‐stimulating factor

All‐cause mortality · DCM (non‐ischaemic)

It is very uncertain whether stem cell therapy (any type) changes all‐cause mortality compared with peripheral therapy with granulocyte colony‐stimulating factor (very low certainty).

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
RR 0.46 [0.16, 1.31]
3 studies · 195 participants
Very low

IF vs CER (short term)

All‐cause mortality · the prevention of cardiovascular disease

The review found no eligible studies for this question.

1 finding from 1 review

Intermittent fasting for the prevention of cardiovascular disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IF vs CER (medium term)

All‐cause mortality · the prevention of cardiovascular disease

The review found no eligible studies for this question.

1 finding from 1 review

Intermittent fasting for the prevention of cardiovascular disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IF vs ad libitum (short term)

All‐cause mortality · the prevention of cardiovascular disease

The review found no eligible studies for this question.

1 finding from 1 review

Intermittent fasting for the prevention of cardiovascular disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Interrupted vs uninterrupted anticoagulation therapy

All‐cause mortality · adults with arrhythmias undergoing catheter ablation

Interrupted showed no clear difference in all‐cause mortality compared with uninterrupted anticoagulation therapy (low certainty).

1 finding from 1 review

Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias 2021 · Cochrane Headline outcomes only
RR 0.34 [0.01, 8.21]
1 study · 442 participants
Low

GLP‐1RA vs placebo

All‐cause mortality · CVD (ASCVD, HF, or both)

GLP‐1RA leads to lower all‐cause mortality compared with placebo (high certainty).

1 finding from 1 review

Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2… 2021 · Cochrane Headline outcomes only
OR 0.88 [0.82, 0.95]
7 studies · 46393 participants
High